〔Abstract〕 Objective To explore the combined application of ergometrine maleate and carbetocin in the prevention and treatment of postpartum hemorrhage caused by uterine inertia. Methods 60 parturient women who gave birth in Shangrao Maternal and Child Health Hospital from January 2020 to March 2022 were selected as the observation objects, and were randomly divided into a control group and an observation group, with 30 cases in each group. The control group was treated with carbetocin postpartum, while the observation group was treated with ergometrine maleate combined with carbetocin. The clinical efficacy, postpartum bleeding and the incidence of adverse reactions were observed and recorded in the two groups. The postpartum vital signs and postpartum blood loss in 2 h were compared between the two groups. Results The total effective rate of the observation group was 96.67 %, higher than 73.33 % of the control group, and the difference was statistically significant (P < 0.05). There was no significant difference in heart rate, systolic blood pressure and diastolic blood pressure 2 h after delivery between the two groups (P > 0.05). The amount of postpartum bleeding at 1 h, 2 h, 6 h and 24 h in the observation group were less than those in the control group, and the differences were statistically significant (P < 0.05). The incidence of postpartum hemorrhage in the observation group was 6.67 %, lower than 26.67 % in the control group, and the difference was statistically significant (P < 0.05). There was no significant difference in the total incidence of adverse drug reactions between the two groups (P > 0.05). Conclusion The combined effect of ergometrine maleate and carbetocin in the prevention and treatment of postpartum hemorrhage due to uterine inertia is exact, which can reduce postpartum hemorrhage and reduce the incidence of postpartum hemorrhage, and has no significant interference with maternal vital signs, less adverse drug reactions, and relatively high treatment safety.